What Thymosin Alpha 1 is
Thymosin Alpha 1 (Tα1) is a naturally occurring 28-residue peptide, originally isolated from thymic extracts, with a long history in immunomodulation research. It has been the subject of substantial pharmaceutical development in some jurisdictions.
Molecular information
- Sequence: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn (N-terminally acetylated)
- Number of residues: 28
- Approximate monoisotopic mass: ~3108 Da (with N-terminal acetylation)
- Physical form: Typically supplied as a white lyophilised powder
Areas of published research
Published research on Thymosin Alpha 1 spans T-cell biology, innate-immunity, antiviral research and adjuvant applications. Its size and N-terminal acetylation are analytically significant: identity confirmation should verify both the correct mass and the presence of the acetyl group (a mass shift of +42 Da relative to the free-amine peptide).
Analytical considerations
Standard research-peptide analytical checks apply: identity confirmation by mass spectrometry (see LC-MS peptide testing explained), purity assessment by reversed-phase HPLC at 214 nm (see what is HPLC peptide testing), and batch-specific documentation (see how to read a peptide COA). Refer to the Peptovia Research Certificate of Analysis page for live examples of the analytical format used for batches supplied.
Further reading
Peer-reviewed literature on Thymosin Alpha 1 is accessible via PubMed and specialist journals. Readers are encouraged to evaluate primary sources directly rather than relying on secondary summaries.
Research Use Only. This profile is an educational overview of Thymosin Alpha 1 as a research peptide. It does not describe or recommend human, veterinary or clinical use. Peptovia Research supplies Thymosin Alpha 1 strictly for in-vitro laboratory research. No dosing, administration or therapeutic guidance is provided or implied.